Huh? I wonder how many of those "small number of reports of tanezumab patients experiencing the worsening of osteoarthritis leading to joint replacement" were actually reported and needed to warrant the suspension of their trials? Or how many compared to the whole? What kind of percentage? What kind of actual numbers? It's nice of them to report this so we can know about it but there leaving me hanging....too many questions![]()
Especially since Pfizer had indicated that "it had seen no safety problem with the drug outside the osteoarthritis study." ....MAKES ME WONDER!
Thanks for posting this article Justin, I'm very interested to read some more about it and start seeing some facts. Do you think the preliminary results from the trial would be up on clinicaltrials.gov by now?



LinkBack URL
About LinkBacks


Reply With Quote

Bookmarks